Estrella Immunopharma, Inc.
ESLA
$0.64
$0.00-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.81M | 3.01M | 2.81M | 3.24M | 3.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.79M | 13.25M | 13.06M | 13.50M | 12.08M |
| Operating Income | -9.79M | -13.25M | -13.06M | -13.50M | -12.08M |
| Income Before Tax | -10.01M | -13.25M | -13.06M | -13.50M | -12.08M |
| Income Tax Expenses | 0.00 | 900.00 | 900.00 | 1.00K | 1.00K |
| Earnings from Continuing Operations | -10.01 | -13.25 | -13.06 | -13.50 | -12.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.01M | -13.25M | -13.06M | -13.50M | -12.08M |
| EBIT | -9.79M | -13.25M | -13.06M | -13.50M | -12.08M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.25 | -0.35 | -0.36 | -0.37 | -0.33 |
| Normalized Basic EPS | -0.16 | -0.22 | -0.22 | -0.23 | -0.21 |
| EPS Diluted | -0.25 | -0.35 | -0.36 | -0.37 | -0.33 |
| Normalized Diluted EPS | -0.16 | -0.22 | -0.22 | -0.23 | -0.21 |
| Average Basic Shares Outstanding | 160.04M | 153.21M | 147.27M | 145.81M | 144.92M |
| Average Diluted Shares Outstanding | 160.04M | 153.21M | 147.27M | 145.81M | 144.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |